subject: Profits Of The Pharmaceutical Industry Prior To May 4 As Highlighted By The Three Major Issues - The [print this page] According to the National Development and Reform Commission recently released report, the pharmaceutical industry to complete before the May total industrial output value of 311.6 billion yuan, up 29%. January-May total profit of 27.8 billion yuan, up 43.6%, higher than the national industry average of 22.7 percent, ranking the 12 major industrial sectors of the third. Chemistry API The first time in more than 5 years of proprietary Chinese medicines, as the industry's second largest source of profits.
Development and Reform Commission said that this year, the pharmaceutical industry continue its rapid growth, production, sales continued rapid growth, markedly improved the overall efficiency, investment growth rebounded.
From the production, marketing point of view, the industry continues to grow. January-May total industrial output value of 311.6 billion yuan to complete, up 29%. Among them, chemical API , Chemicals Preparation , Chinese patent medicines, Traditional Chinese medicine Pieces processing, bio- Biochemical products , Medical equipment and instruments, hygiene materials and medical supplies were more than 20% increase. Sanitary materials and medical supplies, chemical medicine, Traditional Chinese medicine Pieces processing and medical equipment and apparatus manufacturing industry growth rate higher than the industry average. The sales value of 295.54 billion yuan, up 30.3%. Among them, sanitary materials and medical supplies, Chinese Herbal Medicine processing, chemical medicine, medical equipment and instruments, and biological Biochemical products Create five sub-industry growth rate higher than the industry average. The average sales rate of 94.8% over the same period by 0.9 percentage points.
The same time, industrial efficiency increased significantly. January-May total profit of 27.8 billion yuan, up 43.6%, higher than the national industry average of 22.7 percent, ranking the 12 major industrial sectors of the third. Among them, chemical medicine, biological and biochemical products, sanitary materials and medical supplies, and chemical preparations industry growth rate of 4 points higher than the industry average. Chemical raw the first time in more than 5 years of proprietary Chinese medicines, as the industry's second largest source of profits. 1390 loss-making enterprises, industry loss was 22.5%; accumulated losses of 2 billion yuan, up 4.8%.
Stable export growth. January-May export value of 36.8 billion yuan, up 22.9%. Modest recovery in investment. January-May total investment of 28.18 billion yuan in fixed assets, up 18.6%, lagging behind the national average level of manufacturing investment in fixed assets of 12 percent.
Development and Reform Commission said that from the view of the main problems, first is the energy and raw material prices continued to rise. Energy shortage and raw materials prices is the current development of China's pharmaceutical industry is facing the biggest challenge. This year, the snow disaster, earthquake and the impact of soaring international oil prices, China's coal, electricity, oil, transport, agricultural, chemical raw materials and other basic factors of production prices rose markedly different degrees, increased our system Pharmaceutical companies Industry production costs. Meanwhile, with the continuous environmental monitoring efforts to strengthen governance, the environmental costs of large pharmaceutical companies, coupled with the yuan appreciation, export tax rebate rate down, pharmaceutical companies operating in China face enormous cost pressure.
The second is the shortage of blood products, flow control specifications needed. In recent years, China's demand for blood products is rising, but tight supply of raw plasma, blood products manufacturers resulted in underemployment, or even stop production, since the second half of 2006, the hospital blood products in short supply, required by the patients appeared to find their own medicine resolve the situation, which increases the blood products used in safety problems, exacerbated by the market, in particular irregular circulation.
Third is too slow investment growth in the industry. The growth of pharmaceutical industry investment in fixed assets since 2004 has been below the national manufacturing average fixed assets investment growth, although the gap has narrowed this year, but the long run will affect the industry's development potential.
